In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Flexibility is the differentiator in highly competitive RTSM space, says ICON
Read how ICON’s Alyssa Gilliam highlights that “system flexibility, ease of use, integration capabilities, and the ability to support increasingly complex clinical trial supply strategies” have become the defining differentiators in the fast‑evolving RTSM market.
-
Making early AD trials feasible
Early intervention in neurodegenerative diseases, such as Alzheimer’s, offers the potential to slow or prevent disease progression, and increase success rates for clinical development.
-
ICON named to TIME World's Most Sustainable Companies 2025 list
This list ranks the world’s 500 most sustainable companies based on their public commitment to and progress toward sustainability targets. ICON was one of nine Irish-based companies to make this global list, recognising the impact of our ICON Cares programme.
-
The Evolving Cost-Benefit Landscape of Biosimilar Drug Development
The patent cliff for biologic medicines presents an opportunity for developers of biosimilars, but historically there are challenges too. The landscape however is changing, supporting easier paths to market.
-
Regulatory Strategy, The Maestro
As part of Pharma Tech Outlook's Regulatory Strategy, The Maestro Q&A series, ICON answers a range of questions around regulatory in clinical trials, timing and other considerations.
-
NHS App to match patients with clinical trials under 10-year health plan
Dr Andrew Garrett, Executive VP Scientific Operations, ICON, comments on the UK government’s announcement on boost to clinical trials.
-
Exploring updates in adaptive trial safety monitoring
In this JCS article, ICON's experts discuss the key changes in FDA draft guidance on Data Monitoring Committees as it relates to adaptive design trials, providing practical insights and strategies for advanced safety oversight in the modern clinical trial landscape.
-
Preparing to Achieve with Joint Clinical Assessments
Since Regulation (EU) 2021/2282 (HTAR) came into effect, HTDs need to plan for a Joint Clinical Assessment (JCA) in addition to submitting their CTD to the EMA or medical device technical file to their notified body. In this article, ICON discusses this new requirement, factors to consider and the benefits.
-
AI is already delivering pharma value — and not just in drug discovery
This article highlights how AI is already adding value across pharma beyond headline‑grabbing drug discovery, with ICON leveraging its in‑house and proprietary AI tools—like its One Search site‑selection system, resource forecasting, endpoint strategy analytics, and document management platforms—to improve clinical trial efficiency and address enrollment challenges.
-
Yearly Trends in Coverage Rates for GLP-1 RAs in Weight Loss
New research from Symphony Health, an ICON plc company, featured in The American Journal of Managed Care (AMJC), highlights ongoing challenges in patient access to GLP-1 therapies for weight loss.
